Suven Pharmaceuticals Ltd

NSE
SUVENPHAR •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Suven Pharmaceuticals Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
44.27% Gain from 52W Low
11.4
TTM PE Ratio
Below industry Median
45.9
Price to Book Ratio
High in industry
9.8
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is negative
-21.4
RSI
RSI is mid-range
50.9
MFI
MFI is mid-range
56.4

Suven Pharmaceuticals Ltd Key Financials

*All values are in ₹ Cr.

Suven Pharmaceuticals Ltd shareholding Pattern

Promoter
60%
Foreign Institutions
10.1%
Mutual Funds
13.4%
Domestic Institutions
16%
Public
13.9%

Suven Pharmaceuticals Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
14
Bearish Moving Averages
2
5Day EMA
666.30
10Day EMA
661.20
12Day EMA
660.80
20Day EMA
663.40
26Day EMA
665.90
50Day EMA
664.90
100Day EMA
638.70
200Day EMA
592.90
Delivery & Volume
Resistance & Support
671.87
Pivot
Resistance
First Resistance
679.53
Second Resistance
690.67
Third Resistance
698.33
Support
First Support
660.73
Second support
653.07
Third Support
641.93
Relative Strength Index
50.94
Money Flow Index
56.43
MACD
-5.09
MACD Signal
-9.47
Average True Range
22.71
Average Directional Index
21.79
Rate of Change (21)
-5.63
Rate of Change (125)
28.48

Suven Pharmaceuticals Ltd Company background

Founded in: 2018
Managing director: Venkatanaga Kali Vara Prasad Raju Vetukuri
Suven Pharmaceuticals Limited (SPL) is a biopharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process RD, scaleup and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.During the year 201920, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Honble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company. In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/ (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.The company has a massive Rs 320crore capex plan. Suven has invested Rs 120 crore in 201920. The balance is to be invested in 202021.During the year 201920, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Honble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 20192020.As on 31 March 2020,the company has one subsidiary and one associate company under its roof.The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.
Read More

Suven Pharmaceuticals Ltd FAQs

Suven Pharmaceuticals Ltd shares are currently priced at 668.4 on NSE and 667.05 on BSE as of 2/20/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Suven Pharmaceuticals Ltd [SUVENPHAR] share was 38.85. The Suven Pharmaceuticals Ltd [SUVENPHAR] share hit a 1-year low of Rs. 463.3 and a 1-year high of Rs. 768.

The market cap of Suven Pharmaceuticals Ltd is Rs. 17015.12 Cr. as of 2/20/2024 12:00:00 AM.

The PE ratios of Suven Pharmaceuticals Ltd is 44.5 as of 2/20/2024 12:00:00 AM.

The PB ratios of Suven Pharmaceuticals Ltd is 8.71 as of 2/20/2024 12:00:00 AM

The Mutual Fund Shareholding was 13.4% at the end of 2/20/2024 12:00:00 AM.

You can easily buy Suven Pharmaceuticals Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage